🔴 Eupraxia Pharmaceuticals is trading 5% down as no company-specific catalyst is confirmed

Eupraxia Pharmaceuticals is trading at $6.93, down 5.26%, with healthcare-sector weakness a possible contributor.

• XLV fell 1.37% during the regular session amid earnings and drug-pricing concerns.
• No confirmed company-specific catalyst for the October 13 decline was identified. Eupraxia’s RESOLVE-trial update and conference presentations were announced before the session; the company reported persistent symptom responses in its highest-dose cohort.